DK1202736T3 - Nikotin i terapeutisk angiogenese og vasculogenese - Google Patents

Nikotin i terapeutisk angiogenese og vasculogenese

Info

Publication number
DK1202736T3
DK1202736T3 DK00952308T DK00952308T DK1202736T3 DK 1202736 T3 DK1202736 T3 DK 1202736T3 DK 00952308 T DK00952308 T DK 00952308T DK 00952308 T DK00952308 T DK 00952308T DK 1202736 T3 DK1202736 T3 DK 1202736T3
Authority
DK
Denmark
Prior art keywords
nicotine
vasculogenesis
angiogenesis
therapeutic angiogenesis
induction
Prior art date
Application number
DK00952308T
Other languages
Danish (da)
English (en)
Inventor
John Cooke
James Jang
Phillip Tsao
Christopher Heeschen
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK1202736T3 publication Critical patent/DK1202736T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
DK00952308T 1999-07-28 2000-07-28 Nikotin i terapeutisk angiogenese og vasculogenese DK1202736T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14623399P 1999-07-28 1999-07-28
PCT/US2000/020751 WO2001008684A1 (en) 1999-07-28 2000-07-28 Nicotine in therapeutic angiogenesis and vasculogenesis

Publications (1)

Publication Number Publication Date
DK1202736T3 true DK1202736T3 (da) 2008-12-15

Family

ID=22516426

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00952308T DK1202736T3 (da) 1999-07-28 2000-07-28 Nikotin i terapeutisk angiogenese og vasculogenese

Country Status (12)

Country Link
US (2) US6417205B1 (de)
EP (1) EP1202736B1 (de)
JP (2) JP2003505507A (de)
AT (1) ATE408406T1 (de)
AU (1) AU781084B2 (de)
BR (1) BR0012793A (de)
CA (1) CA2380072C (de)
DE (1) DE60040293D1 (de)
DK (1) DK1202736T3 (de)
ES (1) ES2313900T3 (de)
PT (1) PT1202736E (de)
WO (1) WO2001008684A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
US20020192198A1 (en) * 1998-04-21 2002-12-19 Elia James P. Method for growing human organs and suborgans
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
US6692520B1 (en) * 1998-12-15 2004-02-17 C. R. Bard, Inc. Systems and methods for imbedded intramuscular implants
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
ES2313900T3 (es) * 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
ATE485837T1 (de) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
EP1420718A4 (de) * 2000-09-29 2005-12-28 Endovasc Ltd Inc Resorbierbare prothese für eine medizinische behandlung
FR2834039B1 (fr) † 2001-12-21 2004-02-13 Inst Francais Du Petrole Conduite flexible a haute resistance a la compression axiale et sa methode de fabrication
US7045534B2 (en) 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
CA2494506C (en) * 2002-08-02 2009-02-10 Nutraceutical Development Corporation Development of muscle mass in a mammal
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2005117860A1 (en) * 2004-06-03 2005-12-15 Asmacure Ltée Method of treating and preventing arthritis, cutaneous and cardiovascular inflammatory-related diseases using nicotinic receptor agonists
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AU2005277397B2 (en) * 2004-08-18 2011-08-25 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
KR20070084270A (ko) * 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US11076772B2 (en) 2007-03-30 2021-08-03 David G. Silverman Method and system enabling photoplethysmograph measurement of volume status
US9782090B1 (en) 2007-03-30 2017-10-10 David G Silverman Method and system enabling photoplethysmograph measurement of volume status
US8961932B2 (en) * 2007-03-30 2015-02-24 David G. Silverman “Micro-patch” for assessment of the local microvasculature and microcirculatory vasoreactivity
US9877681B2 (en) 2007-03-30 2018-01-30 David G. Silverman “Micro-patch” for assessment of the local microvasculature and microcirculatory vasoreactivity
CA2713049C (en) 2008-01-28 2017-02-28 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
US8173072B2 (en) * 2008-09-22 2012-05-08 Geno Llc Conversation of nitrogen dioxide (NO2) to nitric oxide (NO)
EP2445508B1 (de) 2009-06-22 2018-11-14 VERO Biotech LLC Stickoxidtherapien
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
WO2019200411A1 (en) * 2018-04-13 2019-10-17 The Administrators Of The Tulaneeducational Fund Biomimetic tissue systems and methods of using the same
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8330969D0 (en) 1983-11-21 1983-12-29 Wellcome Found Promoting healing
DE3639418A1 (de) 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
WO1992008482A1 (en) * 1990-11-14 1992-05-29 Uab Research Foundation Compositions for reducing oxidative injury
JPH0641070A (ja) * 1992-03-23 1994-02-15 Sankyo Co Ltd インドール誘導体
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US5318957A (en) 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5508030A (en) 1993-08-05 1996-04-16 Bierman; Howard R. Creating new capillary blood pools for practicing bidirectional medicine
DE4414569A1 (de) * 1994-04-27 1995-11-02 Bayer Ag Verwendung von substituierten Aminen zur Behandlung von Hirnleistungsstörungen
JPH08143454A (ja) * 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
JPH09124593A (ja) * 1995-08-25 1997-05-13 Ono Pharmaceut Co Ltd プロスタグランジンｅ１エステル、それらを含有するリポソーム製剤、およびそれらを含有する医薬
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
US5869037A (en) 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US5866561A (en) 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
RS50069B (sr) 1997-12-31 2009-01-22 Pfizer Products Inc., Aril kondenzovana azapoliciklična jedinjenja
EP1434573A2 (de) * 1998-10-20 2004-07-07 Omeros Corporation Spüllösung und verfahren zur schmerzhinderung und entzündungshemmung
ES2313900T3 (es) * 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
AT409219B (de) 1999-08-13 2002-06-25 Red Bull Gmbh Verwendung von nikotin zum herstellen von arzneimitteln

Also Published As

Publication number Publication date
DE60040293D1 (de) 2008-10-30
PT1202736E (pt) 2008-12-29
JP2010043094A (ja) 2010-02-25
US6417205B1 (en) 2002-07-09
BR0012793A (pt) 2002-04-30
ATE408406T1 (de) 2008-10-15
AU781084B2 (en) 2005-05-05
US7160904B2 (en) 2007-01-09
JP2003505507A (ja) 2003-02-12
EP1202736B1 (de) 2008-09-17
EP1202736A4 (de) 2004-05-19
ES2313900T3 (es) 2009-03-16
CA2380072C (en) 2007-07-10
CA2380072A1 (en) 2001-02-08
AU6503200A (en) 2001-02-19
EP1202736A1 (de) 2002-05-08
US20020128294A1 (en) 2002-09-12
WO2001008684A1 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
DK1202736T3 (da) Nikotin i terapeutisk angiogenese og vasculogenese
DK1187918T4 (da) TEK-antagonister
DK1305286T3 (da) Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling
ATE380807T1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
TR200103574T2 (tr) Amid ikameli/katkılı imidazokinolinler
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
NO20024814L (no) Terapeutiske kombinasjoner av antihypertensive og antiangiogene midler
CY1105225T1 (el) Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
MXPA03008423A (es) Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias.
DK1057828T3 (da) Orale trovafloxacin-suspensioner
NO964238D0 (no) Halofantrin-fri-base for behandling av malaria og blandinger
AU6469401A (en) Pharmaceutically active compounds and methods of use
IT8722641A0 (it) Piedino abbattibile per mobili.
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
DK1229973T3 (da) Gynge til handikappede personer
DK0479093T3 (da) Oligosaccharidderivater og deres anvendelse som lægemidler
DK1147105T3 (da) Optisk aktivt pyridyl-4H-1,2,4-oxadiazinderivat og anvendelse af dette til behandling af karsygdomme
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler